This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
kutluk oktay, New York Medical College Identifier:
First received: July 18, 2007
Last updated: September 24, 2016
Last verified: September 2016
Breast cancer patients are commonly treated with drugs that eggs present in the ovary and may reduce their chance for getting pregnant. Their fertility can be preserved by stimulating their ovaries, collecting multiple eggs, fertilize them in the lab and freeze them. Ovarian stimulation increase their estrogen levels in blood.this may stimulate their cancer and increase chance for recurrence. If a medicine that prevent estrogen rise is used (letrozole), this may increase the safety of stimulation. In this study we compared ovarian stimulation in breast cancer patients using letrozole with those who did not undergo stimulation and showed that there is no increase risk for recurrence after a median follow up of 2 years

Condition Intervention
Breast Cancer Procedure: Ovarian stimulation in vitro fertilization cryopreservation

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients Undergoing Embryo or Oocyte Cryopreservation: A Prospective Controlled Follow up Study

Resource links provided by NLM:

Further study details as provided by kutluk oktay, New York Medical College:

Primary Outcome Measures:
  • Breast cancer relapse free survival after ovarian stimulation [ Time Frame: after chemotherapy to end of follow up ]

Secondary Outcome Measures:
  • Estradiol level, number of embryos cryopreserved, clinical pregnancy rate, ovarian reserve after chemotherapy [ Time Frame: during stimulation, after stimulation and 1-2 years after chemotherapy ]

Estimated Enrollment: 100
Study Start Date: January 2002
Estimated Study Completion Date: September 2020
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: letrozole
ovarian stimulation after breast cancer diagnosis and before breast cancer treatment
Procedure: Ovarian stimulation in vitro fertilization cryopreservation
Letrozole 5 mg/day during ovarian stimulation
No Intervention: control
No ovarian stimulation before breast cancer treatment

Detailed Description:

215 women with breast cancer were evaluated for fertility preservation before chemotherapy. Of those, 79 elected to undergo controlled ovarian stimulation (COH) with letrozole and gonadotropins for embryo or oocyte cryopreservation. The 136 patients who declined served as controls.There were no significant differences between the study and control groups regarding age at diagnosis, breast cancer prognostic parameters (tumor size, grade, number of positive lymph nodes, estrogen receptor status, her2-neu overexpression and vascular space invasion), and chemotherapy regimens. There was no difference between the two groups in the projected 10 year relapse, breast cancer specific mortality or overall mortality. There were 3 recurrences or contralateral breast cancers (2 distant, 1 locoregional) in the letrozole group, and 11 in the control group (9 distant, 1 locoregional, 1 contralateral breast).

Comparison; breast cancer patients that underwent ovarian stimulation with letrozole+gonadotropins and those who declined ovarian stimulation.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-45 years
  • Biopsy proven breast cancer
  • No prior chemotherapy or oophorectomy
  • Regular menstrual cycles
  • Normal basal FSH and estradiol

Exclusion Criteria:

  • Stage 4 breast cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00504699

United States, New York
Valhalla, New York, United States, 10595
Sponsors and Collaborators
New York Medical College
Principal Investigator: Kutluk H Oktay, MD, FACOG IFP
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: kutluk oktay, PI, New York Medical College Identifier: NCT00504699     History of Changes
Other Study ID Numbers: 0110005172
Study First Received: July 18, 2007
Last Updated: September 24, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by kutluk oktay, New York Medical College:
breast cancer
ovarian stimulation
aromatase inhibitors
fertility preservation

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 20, 2017